Intra-Cellular Therapies, Inc.
ITCIDelisted Apr 2, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001567514
Intra-Cellular Therapies, Inc. was delisted on Apr 2, 2025; its insiders filed their last Form 4 on Apr 2, 2025; 395 institutions reported holding it in 13F filings for Q1 2025, worth $13.6B in total; Soros Fund Management was the only superinvestor holding it.
Q4 2022 vs. Q3 2022
How the institutions holding Intra-Cellular Therapies, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 274 | 3 | 283 | +12 |
| Shares | 83.5M | 7.26K | 83.3M | −178.1K (−0.2%) |
| Value | $3.89B | $337.2K | $4.41B | +$523.2M (+13.5%) |
3 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (48)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
Sold out (36)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
Not filed for Q4 2022 yet (3)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Jefferies Group LLC | 6,365 | $296.2K |
| FourThought Financial, LLC | 889 | $41.0K |
| Wipfli Financial Advisors LLC, | 8 | $0 |